بررسی ذخیره‌ی ضربان قلب و C-Reactive Protein با حساسیت بالا در افراد با و بدون سندرم متابولیک

نوع مقاله : مقاله های پژوهشی

نویسندگان

1 دانشیار، مرکز تحقیقات قلب و عروق اصفهان، پژوهشکده‌ی قلب و عروق اصفهان، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

2 متخصص قلب و عروق، گروه قلب، دانشکده‌ی پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

3 دانشیار، مرکز تحقیقات بازتوانی قلبی، پژوهشکده‌ی قلب و عروق اصفهان، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

چکیده

مقدمه: عدم افزایش مناسب ضربان قلب متناسب با ورزش باعث پیش‌آگهی نامناسب بیماران قلبی می‌شود. علاوه بر این، سطوح فاکتورهای التهابی نظیر C-reactive protein با حساسیت بالا (hs-CRP یا High-sensitivity CRP) با آترواسکروز در ارتباط می‌باشد. در این مطالعه، این دو فاکتور در افراد با و بدون سندرم متابولیک بررسی شدند.روش‌ها: این مطالعه بر روی 123 بیمار با سندرم متابولیک و 203 بیمار بدون سندرم متابولیک که به طور تصادفی از شرکت کنندگان مطالعه‌ی کوهورت اصفهان انتخاب شده بودند، انجام گرفت. اطلاعات دموگرافیک، دور کمر، فشار خون، قد و وزن شرکت کنندگان ثبت شد. سپس، سطح سرمی تری‌گلیسرید (Triglyceride یا TG)، قند ناشتای خون ( Fasting blood sugarیا FBS)، کلسترول تام (Total cholesterol یا TC)، لیپوپروتئین با چگالی بالا (High density lipoprotein یا HDL-c)، لیپوپروتئین با چگالی پایین (Low-density lipoprotein یا LDL-c) و hs-CRP اندازه‌گیری شد. تست ورزش بر اساس پروتکل استاندارد Bruce انجام گردید و ذخیره‌ی ضربات قلب (HRR یا Heart rate reserve) ثبت شد. اطلاعات با تنظیم بر اساس سن هر شرکت کننده با استفاده از آزمون آماری Student’s t و رگرسیون خطی بررسی شد.یافته‌ها: متوسط سن در افراد با سندرم متابولیک 60/7 ± 29/54 و در افراد بدون سندرم متابولیک 61/8 ± 16/54 سال بود که تفاوت آماری معنی‌داری نداشت‌. در افراد با و بدون سندرم متابولیک به ترتیب میزان LDL-c برابر 55/29 ± 12/125 و 54/24 ± 17/116 میلی‌گرم بر دسی‌لیتر، میزان TG 49/184 ± 99/259 و 65/61 ± 38/140 میلی‌گرم بر دسی‌لیتر، میزان FBS برابر 46/48 ± 13/107 و 90/9 ± 81/81 میلی‌گرم بر دسی‌لیتر، میزان فشار خون سیستولیک برابر 15/15 ± 73/130 و 69/13 ± 06/116 میلی‌متر جیوه و میزان فشار خون دیاستولیک برابر 70/8 ± 84/28 و 69/6 ± 52/76 میلی‌متر جیوه بود و همه‌ی موارد از نظر آماری اختلاف معنی‌دار داشت. دو گروه از نظر ذخیره‌ی ضربان قلب تفاوت معنی‌داری نداشتند (027/0 = P) ولی میزان hs-CRP در گروه با سندرم متابولیک به وضوح بالاتر بود (02/0 = P).نتیجه‌گیری: ما در این مطالعه نتوانستیم ارتباطی بین ذخیره‌ی ضربات قلب و سندرم متابولیک نشان دهیم ولی ارتباط بین hs-CRP و سندرم متابولیک نشان‌دهنده‌ی افزایش میزان hs-CRP به عنوان یک فاکتور التهابی در افراد با سندرم متابولیک است. 

کلیدواژه‌ها

عنوان مقاله [English]

Comparing Heart Rate Reserve and High-Sensitivity C-Reactive Protein in Patients with and without Metabolic Syndrome

نویسندگان [English]

  • Jafar Golshahi 1
  • Yosef Khaledi 2
  • Esmaeil Aghababaei 2
  • Masoumeh Sadeghi 3
  • Mohammad Hashemi 3
  • Hamid Sanei 1
1 Associate Professor, Isfahan Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
2 Cardiologist, Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 Associate Professor, Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
چکیده [English]

Background: Absence of increase in heart rate in response to exercise indicates poor prognosis. Inflammatory factors as C-reactive protein (CRP) are associated with atherosclerosis. In this study, these two factors were compared in patients with and without metabolic syndrome.Methods: 203 individuals without and 123 individuals with metabolic syndrome were selected randomly from Isfahan Cohort Study and their demographic data, wait circumference, height and weight were recorded. Also, serum triglyceride (TG), fasting blood sugar (FBS), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), and high-sensitivity CRP (hs-CRP) levels were measured. Heart rate reserve (HRR) was determined through exercise test carried out according to the Bruce standard protocol. The age-adjusted data was analyzed by generalized linear regression and student's t test.Findings: The mean ages of individuals without and with metabolic syndrome were 54.16 ± 8.61 and 54.29 ± 7.60 years, respectively (P = 0.890). The mean LDL levels in subjects without and with the metabolic syndrome were 116.17 ± 24.04 and 120.12 ± 29.55 mg/dl while mean TG levels were 140.38 ± 61.65 and 259.99 ± 184.49 mg/dl and mean FBS levels were 81.81 ± 9.90 mg/dl and 107.13 ± 48.46 mg/dl, respectively; all the differences were statistically significant. The mean systolic blood pressure was 116.06 ± 13.69 mmHg in persons without metabolic syndrome and 130.73 ± 15.15 mmHg in patients with the syndrome. The values for mean diastolic levels in the two groups were 76.52 ± 6.69 and 82.84 ± 8.7 mmHg, respectively. Hs-CRP level in the metabolic syndrome group was significantly higher than the other group (P = 0.02) while HRR did not show significant difference in the two groups (P = 0.27).Conclusion: In our study, no relationship was documented between HRR and the metabolic syndrome. However, elevated levels of hs-CRP were recorded in patients with metabolic syndrome.

کلیدواژه‌ها [English]

  • Metabolic Syndrome
  • Exercise test
  • Heart rate reserve
  • High-Sensitivity C-Reactive Protein

مراجع

  1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37(12): 1595-607.
  2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287(3): 356-9.
  3. Ozanne SE, Hales CN. Early programming of glucose-insulin metabolism. Trends Endocrinol Metab 2002; 13(9): 368-73.
  4. Chaitman BR. Exercise stress testing. In: Libby P, Bonow RO, Mann DL, Zipes DP, editors. Braunwald's heart disease: a textbook of cardiovascular medicine. 8th ed. Philadelphia, PA: Saunders; 2007. p. 197-205.
  5. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002; 40(8): 1531-40.
  6. Vivekananthan DP, Blackstone EH, Pothier CE, Lauer MS. Heart rate recovery after exercise is a predictor of mortality, independent of the angiographic severity of coronary disease. J Am Coll Cardiol 2003; 42(5): 831-8.
  7. Froelicher VF, Myers J. Exercise and the heart. Philadelphia, PA: Saunders; 2006.
  8. Elhendy A, Mahoney DW, Khandheria BK, Burger K, Pellikka PA. Prognostic significance of impairment of heart rate response to exercise: impact of left ventricular function and myocardial ischemia. J Am Coll Cardiol 2003; 42(5): 823-30.
  9. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352(19): 1951-8.
  10. Wei M, Kampert JB, Barlow CE, Nichaman MZ, Gibbons LW, Paffenbarger RS, Jr., et al. Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men. JAMA 1999; 282(16): 1547-53.
  11. Mora S, Redberg RF, Cui Y, Whiteman MK, Flaws JA, Sharrett AR, et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. JAMA 2003; 290(12): 1600-7.
  12. Chaitman BR. Abnormal heart rate responses to exercise predict increased long-term mortality regardless of coronary disease extent: the question is why? J Am Coll Cardiol 2003; 42(5): 839-41.
  13. Morise AP. Heart rate recovery: predictor of risk today and target of therapy tomorrow? Circulation 2004; 110(18): 2778-80.
  14. Fletcher GF, Balady GJ, Amsterdam EA, Chaitman B, Eckel R, Fleg J, et al. Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104(14): 1694-740.
  15. Mark DB, Lauer MS. Exercise capacity: the prognostic variable that doesn't get enough respect. Circulation 2003; 108(13): 1534-6.
  16. Falcone C, Buzzi MP, Klersy C, Schwartz PJ. Rapid heart rate increase at onset of exercise predicts adverse cardiac events in patients with coronary artery disease. Circulation 2005; 112(13): 1959-64.
  17. Huffman FG, Gomez GP, Zarini GG. Metabolic syndrome and high-sensitivity C-reactive protein in Cubans. Ethn Dis 2009; 19(2): 115-20.
  18. Nakamura H, Ito H, Egami Y, Kaji Y, Maruyama T, Koike G, et al. Waist circumference is the main determinant of elevated C-reactive protein in metabolic syndrome. Diabetes Res Clin Pract 2008; 79(2): 330-6.
  19. Bahceci M, Gokalp D, Bahceci S, Tuzcu A, Atmaca S, Arikan S. The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults? J Endocrinol Invest 2007; 30(3): 210-4.
  20. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111(11): 1448-54.
  21. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 2005; 69(1): 29-35.
  22. Lee WY, Park JS, Noh SY, Rhee EJ, Sung KC, Kim BS, et al. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int J Cardiol 2004; 97(1): 101-6.
  23. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107(3): 391-7.
  24. Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109(3): 433-8.
  25. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110(10): 1251-7.
  26. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28(2): 385-90.
  27. Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation. Atherosclerosis 2002; 165(2): 285-92.
  28. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93(2): 136-41.
  29. Brinkworth GD, Noakes M, Buckley JD, Clifton PM. Weight loss improves heart rate recovery in overweight and obese men with features of the metabolic syndrome. Am Heart J 2006; 152(4): 693-6.
  30. Sarraf-Zadegan N, Boshtam M, Malekafzali H, Bashardoost N, Sayed-Tabatabaei FA, Rafiei M, et al. Secular trends in cardiovascular mortality in Iran, with special reference to Isfahan. Acta Cardiol 1999; 54(6): 327-33.
  31. Sarraf-Zadegan N, Sayed-Tabatabaei FA, Bashardoost N, Maleki A, Totonchi M, Habibi HR, et al. The prevalence of coronary artery disease in an urban population in Isfahan, Iran. Acta Cardiol 1999; 54(5): 257-63.
  32. Sarrafzadegan N, Kelishadi R, Baghaei A, Hussein SG, Malekafzali H, Mohammadifard N, et al. Metabolic syndrome: an emerging public health problem in Iranian women: Isfahan Healthy Heart Program. Int J Cardiol 2008; 131(1): 90-6.
  33. Sarrafzadegan N, Baghaei A, Sadri G, Kelishadi R, Malekafzali H, Boshtam M, et al. Isfahan healthy heart program: Evaluation of comprehensive, community-based interventions for non-communicable disease prevention. Prevention and Control 2006; 2(2): 73-84.
  34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.
  35. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-253.
  36. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982; 28(6): 1379-88.
  37. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18(6): 499-502.
  38. World Health Organization. Cardiovascular Diseases Unit. Monica manual. Geneva, Switzerlan: World Health Organization; 1990.
  39. Regitz-Zagrosek V, Lehmkuhl E, Mahmoodzadeh S. Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. Gend Med 2007; 4(Suppl B): S162-S177.
  40. Nilsson G, Hedberg P, Jonason T, Lonnberg I, Ohrvik J. Heart rate recovery is more strongly associated with the metabolic syndrome, waist circumference, and insulin sensitivity in women than in men among the elderly in the general population. Am Heart J 2007; 154(3): 460-7.
مجله دانشکده پزشکی اصفهان
دوره 32، شماره 312 - شماره پیاپی 312
بهمن و اسفند 1393
صفحه 2085-2093

فایل ها

سابقه مقاله

  • تاریخ دریافت: 02 مرداد 1393
  • تاریخ بازنگری: 11 آبان 1403
  • تاریخ پذیرش: 17 فروردین 1401

هم رسانی

ارجاع به این مقاله

آمار